TMS Co., Ltd. (JP:4891) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TMS Co., Ltd. has announced the publication of Phase 2a clinical trial results for JX10 (TMS-007), a potential treatment for acute ischemic stroke, in a leading medical journal. The study demonstrated significant efficacy and safety, highlighting JX10’s potential as a novel therapeutic option with an extended treatment window. This development marks a promising step forward in addressing the needs of a largely underserved patient population.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.